Perhaps more importantly, we now show that FASN is a key biological determinant of the molecular program through which HRG overexpression promotes the acquisition of an endocrine-resistant phenotype in ER+/HER2− breast cancer cells. The gene discussed is ESR1; the disease is breast carcinoma.